<DOC>
	<DOCNO>NCT01386086</DOCNO>
	<brief_summary>Currently control data management postpartum depression fail respond adequate antidepressant therapy . The investigator recently report large number patient respond addition atypical neuroleptic fail antidepressant trial . Aripiprazole use adjunctively antidepressants effective patient resistant depression study patient resistant postpartum depression . The investigator propose conduct 6 week open-label study ass effectiveness tolerability aripiprazole use adjunctively antidepressants patient resistant postpartum depression .</brief_summary>
	<brief_title>Aripiprazole Resistant Postpartum Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression , Postpartum</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Euthyroid outpatient age 18 45 year age A DSMIV diagnosis major depressive disorder episode onset within 3 month delivery A 17item HAMD score 18 Inadequate response least one antidepressant drug define &lt; 50 % reduction severity depression duration &gt; 6 week ( &gt; 8 week fluoxetine ) , determine Massachusetts General Hospital Antidepressant Response Questionnaire . Patients score 18 17item HAMD eligible participate study . The primary efficacy endpoint mean change MADRS score , secondary endpoint mean change HAMD score &gt; For patient psychotropic drug ( antidepressant ) prior washout period two week Ability understand English provide inform consent Women deliver healthy baby close term ( 3742 week ) Use adequate contraception &gt; Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study least 4 week last dose study drug minimize risk pregnancy . Prior study enrollment , woman childbearing potential must advise importance avoid pregnancy trial participation potential risk factor unintentional pregnancy . WOCBP include woman experience menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Women use oral contraceptive , hormonal contraceptive ( vaginal product , skin patch , implant injectable product ) , mechanical product intrauterine device barrier method ( diaphragm , condom , spermicide ) prevent pregnancy , practice abstinence partner sterile ( eg , vasectomy ) consider childbearing potential . WOCBP must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 7 day start investigational product . A subject 's male partner father potential must use adequate method contraception avoid conception throughout study [ least 4 week last dose study drug ] minimize risk pregnancy . Women onset major depressive disorder pregnancy Presence another current Axis I disorder bipolar disorder , psychotic disorder obsessive compulsive disorder history psychosis history postpartum mood disorder psychotic feature Presence psychotic symptom History alcohol substance abuse within 12 month screen Any Axis II diagnosis suggestive likely noncompliance study requirement nonresponsiveness pharmacotherapy . Women receive psychotherapy Women receive psychotropic drug allow study protocol Use quinolone antibiotic ciprofloxacin Significant medical illness end stage renal disease , uncontrolled narrow angle glaucoma liver disease Women consider high risk suicidethose actively suicidal score â‰¥ 3 item # 3 17item HAMD ; woman , opinion Investigator , deem risk cause harm baby Women nursing/breastfeeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Aripiprazole</keyword>
	<keyword>adjunctive therapy</keyword>
	<keyword>mood stabilizer</keyword>
	<keyword>major depressive disorder</keyword>
	<keyword>postpartum</keyword>
	<keyword>Augmentation therapy</keyword>
	<keyword>resistant</keyword>
</DOC>